Questions & explanations
1. Compare intrathecal chemotherapy via lumbar puncture versus via Ommaya reservoir in lymphomatous meningitis.
Intrathecal chemotherapy via lumbar puncture involves injecting drugs into the lower spine with a needle each time. This can be painful and requires the patient to lie still for a while. The drug may not spread evenly throughout the fluid around the brain. Using an Ommaya reservoir, the drug is injected into a device under the scalp, and it flows directly into the brain's fluid spaces. This method ensures better drug distribution to the meninges and is more comfortable for repeated treatments. The reservoir also allows easier fluid sampling for tests. However, placing the reservoir is a minor surgery that carries risks like infection or blockage. Lumbar puncture is simpler and avoids surgery, but may need to be done more often.
2. What is the main difference between dense granules and alpha granules in platelets?
Platelets have two main types of storage granules: dense granules and alpha granules. Dense granules store small molecules like ADP, ATP, serotonin, and calcium, which help activate other platelets. Alpha granules store larger proteins such as fibrinogen, von Willebrand factor, and platelet factor 4, which aid in clot formation and wound healing. A defect in dense granules mainly impairs platelet aggregation, while a defect in alpha granules affects clotting and inflammation. For example, in dense granule deficiency, platelets cannot release enough ADP to recruit more platelets, causing bleeding problems. In alpha granule deficiency (Gray platelet syndrome), platelets appear gray under a microscope due to missing granules.
3. Compare watchful waiting versus early treatment for a patient with indolent lymphoma who has no GELF criteria.
Watchful waiting means no active treatment, only regular monitoring. Early treatment means starting chemotherapy, immunotherapy, or radiation right away. Studies show that for patients without GELF criteria, early treatment does not improve overall survival compared to watchful waiting. Watchful waiting avoids side effects of treatment like nausea, infection risk, and fatigue. It also delays drug resistance. However, some patients feel anxious without treatment. Early treatment might shrink lymph nodes faster and relieve anxiety, but it exposes the patient to toxicity. The choice depends on patient preference and disease features. Most guidelines recommend watchful waiting for asymptomatic indolent lymphoma.
4. What are the GELF criteria for watchful waiting in indolent lymphomas?
GELF criteria are a set of rules used to decide when to start treatment for indolent lymphomas like follicular lymphoma. Indolent lymphomas grow slowly and may not need immediate therapy. The GELF criteria include: having three or more lymph node areas involved, each node larger than 3 cm, or a single node larger than 7 cm. Also, symptoms like fever, night sweats, or weight loss, called B symptoms, are a criterion. Other criteria are an enlarged spleen, fluid buildup in the belly, or low blood cell counts. If none of these are present, doctors may choose watchful waiting, meaning they monitor the patient closely without treatment. Treatment starts only if the disease progresses or symptoms appear.
5. What should a person on emicizumab do if they get a bleed?
If a person on emicizumab has a bleed, they should use a rescue medicine as prescribed by their doctor. For mild bleeds, they might use factor VIII concentrate if they do not have inhibitors, or a bypassing agent like activated prothrombin complex concentrate (aPCC) or recombinant factor VIIa if they have inhibitors. They should not use high doses of aPCC because it can cause blood clots when combined with emicizumab. The doctor will give a specific plan. They should also apply pressure and ice to the bleed and rest the area. If the bleed is severe or in a dangerous place like the head, they must go to the emergency room. Regular monitoring with blood tests is not needed for emicizumab levels.
6. How does an Ommaya reservoir help in treating lymphomatous meningitis?
An Ommaya reservoir is a small device placed under the scalp that connects to a tube going into the fluid-filled space around the brain. It allows doctors to give chemotherapy drugs directly into the cerebrospinal fluid without repeated spinal taps. This makes treatment more comfortable and reliable because the drugs reach the meninges evenly. The reservoir can also be used to remove fluid for testing. It reduces the risk of infection and bleeding from multiple needle sticks. Patients with lymphomatous meningitis often need several doses of intrathecal chemotherapy, and the reservoir simplifies this process. After treatment, the reservoir may be removed if no longer needed.
7. What problems can happen with factor replacement therapy?
The main problem is developing inhibitors, which are antibodies that attack the infused factor and stop it from working. This happens in about 20-30% of people with severe hemophilia A. Inhibitors make bleeding harder to control and require different treatments like bypassing agents. Other problems include allergic reactions (rare), infections from plasma-derived products (very rare now), and difficulty with venous access (finding a vein to inject). Some people may have pain or swelling at the injection site. Regular monitoring with blood tests helps detect inhibitors early. Treatment for inhibitors involves immune tolerance therapy or using other clotting products.
8. How does emicizumab compare to factor replacement therapy for preventing bleeds?
Emicizumab is given as a small shot under the skin once a week, while factor replacement is given into a vein several times a week. Emicizumab is much more convenient and less painful, especially for children. It also works even if the person has inhibitors to factor VIII. Studies show emicizumab reduces bleeds by about 87% compared to no prevention, and it is as good as or better than factor prophylaxis for people without inhibitors. However, emicizumab does not replace factor for treating bleeds. It is also very expensive. Some people may develop side effects like redness at the injection site or, rarely, blood clots if used with certain other medicines.
9. Can emicizumab be used in children with hemophilia A?
Yes, emicizumab is approved for children of all ages with hemophilia A, including babies. It is especially useful for children because the shots under the skin are less scary than frequent needle sticks into veins. Children with inhibitors also benefit greatly. The dose is based on weight, and the shot can be given by a parent after training. It helps prevent joint bleeds that can cause long-term damage. However, children must still be watched for breakthrough bleeds and need rescue treatment if bleeding occurs. The safety and effectiveness in children are similar to adults. Starting emicizumab early can improve quality of life and reduce hospital visits.
10. Compare anemia of chronic disease with iron deficiency anemia.
Both anemias cause low red blood cells and tiredness, but they have different causes and lab results. In iron deficiency anemia, the body has too little iron stored, so ferritin is low and iron-binding capacity is high. In anemia of chronic disease, iron stores are normal or high, so ferritin is normal or high and iron-binding capacity is low. Iron deficiency is treated with iron supplements, while anemia of chronic disease is treated by controlling the underlying illness. The red blood cells in iron deficiency are often very small, while in chronic disease they may be only slightly small. A simple blood test for ferritin helps tell them apart.
11. What is fresh frozen plasma (FFP) and when is it used?
Fresh frozen plasma (FFP) is the liquid part of blood that contains all clotting factors. It is made from donated blood and frozen quickly to keep the factors active. FFP is given through a vein to replace missing clotting factors when a specific factor concentrate is not available. It is used for bleeding due to liver disease, warfarin overdose, or massive transfusion. It can also be used for some rare clotting factor deficiencies. FFP must be matched to the patient's blood type. It carries a small risk of allergic reactions and infections. It is not the first choice for hemophilia because factor concentrates are safer and more effective.
12. Why might a doctor choose recombinant factor over plasma-derived factor?
Recombinant factors are made in a lab using DNA technology, so they do not come from human blood. This means there is no risk of passing infections like viruses that could be in donated blood. Plasma-derived factors go through cleaning steps to remove viruses, but a very small risk remains. Recombinant factors are also more consistent in quality because they are produced in a controlled way. However, they are usually more expensive than plasma-derived ones. Some people may develop antibodies (called inhibitors) to either type, which makes the treatment less effective. The choice depends on cost, availability, and patient preference.